Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.54 |
| ▸ | HPD | P32754 | 6/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18829235 | 0.87 | MRGPRX4 (0.53) | MRGPRX4HPDADRB2ADRB1HTR1A | |
| SCHEMBL19883576 | 0.86 | MRGPRX4 (0.54) | MRGPRX4HPDADRB2ADRB1HTR1A | |
| SCHEMBL17702832 | 0.80 | GAA (0.39) | MRGPRX4HPDTSHRMAOAMAOB | |
| SCHEMBL6121177 | 0.75 | MAOA (0.70) | HPDMAOAMAOB | |
| SCHEMBL29726325 | 0.75 | MAOA (0.70) | HPDMAOAMAOB | |
| SCHEMBL5101144 | 0.74 | MRGPRX4 (0.74) | MRGPRX4HPDADRB2ADRB1HTR1A | |
| SCHEMBL31318410 | 0.74 | MRGPRX4 (0.74) | MRGPRX4HPDADRB2ADRB1HTR1A | |
| SCHEMBL8753959 | 0.74 | MRGPRX4 (0.57) | MRGPRX4ADRB2ADRB1HTR1AADRB3 | |
| SCHEMBL28349971 | 0.74 | MRGPRX4 (0.59) | MRGPRX4SLC6A4MAOAMAOBABCB1 | |
| SCHEMBL5270656 | 0.72 | MRGPRX4 (0.56) | MRGPRX4ADRB2ADRB1HTR1AADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10807990-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-10800789-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2020-04-23 | — | — | US | disclosed |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-05 | — | — | US | disclosed |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-11-07 | — | — | US | disclosed |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013075029-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2012068234-A2 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
| US-20200071337-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
| US-20190276468-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
| US-10807990-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
| US-20200123132-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | MRGPRX4 3773/4885HPD 3130/4885ADRB2 4732/4885 |
| US-10800789-B2 | Antiviral compounds | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
| US-20210053981-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
| US-20190337960-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | MRGPRX4 3973/4885HPD 4146/4885ADRB2 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.